September 2016

The XII Mediterranean Marathon will run to overcome autoimmune diseases

On October 12th, the Mediterranean Marathon, one of the consolidated sports programming dating in the country, reaches its XII edition. Under the slogan “Do not run, fly!” participants in the race can make, voluntarily and for the first time in the history of this competition, a charitable contribution to a research project of the Bellvitge […]

The XII Mediterranean Marathon will run to overcome autoimmune diseases Read More »

When learning is fun – scientists prove how the brain simulates external rewards to boost memory formation

Humans can learn effectively, especially when they are externally rewarded (for example, with money or desirable incentives after their actions). Instead of externally-triggered learning (carrot-based learning), self-organised or intrinsically driven learning refers to those learning processes without any objective reward. If you think of it, humans are often involved in these types of rewardless learning

When learning is fun – scientists prove how the brain simulates external rewards to boost memory formation Read More »

Scientists find mutations associated with unusual forms of Rett syndrome

An article published in the journal Human Genetics by Manel Esteller, Director of the Program for Epigenetics and Cancer Biology (PEBC) of Bellvitge Biomedical Research Institute (IDIBELL), ICREA researcher and Professor of Genetics of the University of Barcelona, ​​discovers mutations in genes associated with the development of atypical Rett syndrome, and distinguishes this clinical entity

Scientists find mutations associated with unusual forms of Rett syndrome Read More »

Scientists prove the effectiveness of a new combination of drugs in a type of incurable lung cancer

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Montse Sanchez-Cespedes, have demonstrated in in vitro and in vivo studies the effectiveness of a new drug combination in the treatment of a subtype of lung cancer. The study, published by the journal Oncogene, follows a promising lead for a disease for which there

Scientists prove the effectiveness of a new combination of drugs in a type of incurable lung cancer Read More »

Magda Martí, new managing director of IDIBELL

Today September 20th, Ms. Magda Martí has been officially presented as the new Managing Director of IDIBELL to all administration and service staff. Martin joined IDIBELL last September 12th replacing Mr. Alexandre Puerto. Magda Martí comes from the Quality and Health Assessment Agency of Catalonia (AQuAS), where she worked for more than eight years as

Magda Martí, new managing director of IDIBELL Read More »

INPhINIT, the new ”la Caixa” Doctoral Fellowship Programme

INPhINIT a new doctoral fellowship programme international Early-Stage Researchers supporting the best scientific talent fostering innovative and high-quality research in Spain 57 Early-Stage Researchers of any nationality, 3-year employment contract at the Research Centre of their choice personal career development plan mobility opportunities, complementary training courses and workshops. European Commission’s support Horizon 2020 Marie Skłodowska-Curie Actions – COFUND programme highest standards for research training

INPhINIT, the new ”la Caixa” Doctoral Fellowship Programme Read More »

Therapeutic RANK inhibition reduces breast cancer recurrence

Researchers at the Institute of Biomedical Research of Bellvitge (IDIBELL), led by Dr. Eva Gonzalez-Suarez, have shown that pharmacological and genetic inhibition of signaling pathway RANK / RANKL leads to a significant reduction in recurrences and metastases in breast cancer in a mouse animal model. Their findings, published in Cancer Research, suggest that RANK inhibitors

Therapeutic RANK inhibition reduces breast cancer recurrence Read More »

Dr. Conxi Lázaro is awarded the Theodor Schwann Prize for his research in the field of neurofibromatosis

Dr. Conxi Lázaro, director of the Molecular Diagnostic Unit of the ICO-IDIBELL Hereditary Cancer Program, has received the prestigious Theodor Schwann prize awarded by the European Association of Neurofibromatosis. This award is named after the German physiologist who identified the cells responsible for tumors present in patients with neurofibromatosis type 1, the Schwann cells. Dr.

Dr. Conxi Lázaro is awarded the Theodor Schwann Prize for his research in the field of neurofibromatosis Read More »

Scroll to Top